Is pregabalin and duloxetine capable enough for diabetic neuropathic pain?
The nerve problems arising due to diabetes causes the diabetes neuropathic pain. A study was done to compare the efficacy and cost effectiveness of Pregabalin and Duloxetine used in Diabetic Neuropathic Pain.
A 6-month study was employed in a diabetic clinic of a 500 bedded tertiary care hospital in South India. Subjects were picked who were diagnosed with diabetic neuropathy and not treated with Pregabalin and Duloxetine or any other drugs of its type. NPS and Neuro QoL questionnaires were used to attain the data. Cost of both drugs was calculated as the mean of the price of 3 major common brands of those drugs. Comparison of the mean difference produced by both drugs in NPS and QoL scores was used to estimate comparative efficacy. ICER ratio was used to depict the cost effectiveness.
The repercussion of study has revealed that duloxetine dominates over pregabalin because significant improvement in the mean difference of NPS and Neuro QoL scores of both Pregabalin (p=<0.001) and duloxetine (p=<0.001) before and after the therapy was observed. The mean cost of Pregabalin and duloxetine for 3 months therapy was found to be INR 668.7 and INR 756. Duloxetine manifested a better effect but was more expensive. ICER ratio was calculated and found that a cost of INR 61.47 per extra QoL obtained by Duloxetine.
Both drugs were found to be effective. A significant better improvement in QoL of patients was procured by Duloxetine with comparatively mild increase in the price on managing the cost effective analysis.